Pfizer (PFE) Competitors

Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Which has more risk & volatility, PFE or JNJ?

Pfizer has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.

Do insiders & institutionals hold more shares of PFE or JNJ?

68.4% of Pfizer shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Does the MarketBeat Community prefer PFE or JNJ?

Pfizer received 384 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 68.87% of users gave Pfizer an outperform vote while only 64.81% of users gave Johnson & Johnson an outperform vote.

Company	Underperform	Outperform
Pfizer	Outperform Votes 1511 68.87%	Underperform Votes 683 31.13%
Johnson & Johnson	Outperform Votes 1127 64.81%	Underperform Votes 612 35.19%

Which has higher earnings and valuation, PFE or JNJ?

Johnson & Johnson has higher revenue and earnings than Pfizer. Johnson & Johnson is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.46B	2.22	$8.03B	$1.38	17.69
Johnson & Johnson	$89.33B	4.21	$14.07B	$8.99	17.39

Does the media favor PFE or JNJ?

In the previous week, Pfizer had 24 more articles in the media than Johnson & Johnson. MarketBeat recorded 115 mentions for Pfizer and 91 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.83 beat Pfizer's score of 0.61 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	46 Very Positive mention(s)	17 Positive mention(s)	30 Neutral mention(s)	12 Negative mention(s)	3 Very Negative mention(s)	Positive
Johnson & Johnson	51 Very Positive mention(s)	10 Positive mention(s)	22 Neutral mention(s)	6 Negative mention(s)	2 Very Negative mention(s)	Positive

Is PFE or JNJ a better dividend stock?

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 7.0%. Johnson & Johnson pays an annual dividend of $5.20 per share and has a dividend yield of 3.3%. Pfizer pays out 124.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson pays out 57.8% of its earnings in the form of a dividend. Pfizer has increased its dividend for 16 consecutive years and Johnson & Johnson has increased its dividend for 64 consecutive years.

Do analysts prefer PFE or JNJ?

Pfizer presently has a consensus target price of $29.64, indicating a potential upside of 21.44%. Johnson & Johnson has a consensus target price of $171.82, indicating a potential upside of 9.92%. Given Pfizer's higher probable upside, research analysts clearly believe Pfizer is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	2.53
Johnson & Johnson	0 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.63

Is PFE or JNJ more profitable?

Johnson & Johnson has a net margin of 18.20% compared to Pfizer's net margin of 12.62%. Johnson & Johnson's return on equity of 34.24% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	12.62%	19.47%	8.09%
Johnson & Johnson	18.20%	34.24%	13.63%

Summary

Johnson & Johnson beats Pfizer on 15 of the 22 factors compared between the two stocks.